Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances

Critical Reviews in Oncology/Hematology

Volumn 60, Issue 3, 2006, Pages 181-193

  Nieder, Carsten ^a   Adam, Markus ^a   Molls, Michael ^a   Grosu, Anca L ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chemotherapy; Radiotherapy; Recurrent glioma; Surgery; Treatment

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; BRADYKININ DERIVATIVE; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; GANCICLOVIR; GEFITINIB; HYDROXYUREA; IFOSFAMIDE; IRINOTECAN; LOBRADIMIL; LOMUSTINE; MARIMASTAT; MITOXANTRONE; NIMUSTINE; NITROSOUREA; NSC 374551; ONYX 015; PROCARBAZINE; PROTEIN TYROSINE KINASE INHIBITOR; PSEUDOMONAS EXOTOXIN; T 138067; TAMOXIFEN; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; TOPOTECAN; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; GENE AMPLIFICATION; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNOTHERAPY; NONHUMAN; PATIENT SELECTION; PHOTODYNAMIC THERAPY; POSTOPERATIVE CARE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOIMMUNOTHERAPY; REVIEW; STEREOTAXIC SURGERY; TIME SERIES ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; BRAIN NEOPLASMS; GLIOMA; HUMANS; MIDDLE AGED; PROGNOSIS; RECURRENCE;

EID: 33750719122     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2006.06.007     Document Type: Review

References (94)

1. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 (2005) 987-996
2. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 (2005) 997-1003
3. Nieder C., Grosu A.L., Mehta M.P., Andratschke N., and Molls M. Treatment of malignant gliomas in adults: radiotherapy, chemotherapy and integration of new targeted agents. Expert Rev Neurother 4 (2004) 691-703
4. Nieder C., Grosu A.L., and Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treatment Rev 26 (2000) 397-409
5. Huncharek M., and Muscat J. Treatment of recurrent high grade astrocytomas: results of a systematic review of 1415 patients. Anticancer Res 18 (1998) 1303-1311
6. Brem H., Piantadosi S., Burger P.C., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345 (1995) 1008-1012
7. Bleehen N.M., Freedman L.S., and Stenning S.P. A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Int J Radiat Oncol Biol Phys 16 (1989) 1077-1081
8. Osoba D., Brada M., Yung W.K., et al. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 18 (2000) 1481-1491
9. Yung W.K., Albright R.E., Olson J., et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83 (2000) 588-593
10. Prados M.D., Schold S.C., Fine H.A., et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neurooncol 5 (2003) 96-103
11. Rajkumar S.V., Reid J.M., Novotny P.J., et al. A randomized phase II and pharmakokinetic study of dacarbazine in patients with recurrent glioma. J Neurooncol 49 (2000) 255-261
12. Young B., Oldfield E.H., Markesberry W.R., et al. Re-operation for glioblastoma. J Neurosurg 55 (1981) 917-921
13. Barker F.G., Chang S.M., Gutin P.H., et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42 (1998) 709-720
14. Pinsker M., and Lumenta C. Experience with reoperation on recurrent glioblastoma multiforme. Zentralbl Neurochir 62 (2001) 43-47
15. Olivi A., Grossman S.A., Tatter S., et al. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. J Clin Oncol 21 (2003) 1845-1849
16. Von Eckardstein KL, Reszka R, Kiwit JC. Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma - clinical observations. J Neurooncol 2005, epub.
17. Stylli S.S., Kaye A.H., MacGregor L., et al. Photodynamic therapy of high grade glioma - long term survival. J Clin Neurosci 12 (2005) 389-398
18. Schmidt M.H., Meyer G.A., Reichert K.W., et al. Evaluation of photodynamic therapy near functional brain tissue in patients with recurrent brain tumors. J Neurooncol 67 (2004) 201-207
19. Weber F.W., Floeth F., Asher A., et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl 88 (2003) 93-103
20. Sampson J.H., Akabani G., Archer G.E., et al. Progress report of a phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J Neurooncol 65 (2003) 27-35
21. Dillman R.O., Duma C.M., Schiltz P.M., et al. Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27 (2004) 398-404
22. Chiocca E.A., Abbed K.M., Tatter S., et al. A phase I open-label, dose escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 10 (2004) 958-966
23. Prados M.D., McDermott M., Chang S.M., et al. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a phase I/II multi-institutional trial. J Neurooncol 65 (2003) 269-278
24. Smitt P.S., Driesse M., Wolbers J., et al. Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther 7 (2003) 851-858
25. Pulkkanen K.J., and Yla-Herttuala S. Gene therapy for malignant glioma: current clinical status. Mol Ther 12 (2005) 585-598
26. Lang F.F., Bruner J.M., Fuller G.N., et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21 (2003) 2508-2518
27. Nieder C., Nestle U., Niewald M., Walter K., and Schnabel K. Hyperfractionated reirradiation for malignant glioma. Front Radiat Ther Oncol 33 (1999) 150-157
28. Shepherd S.F., Laing R.W., Cosgrove V.P., et al. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys 37 (1997) 393-398
29. Hudes R.S., Corn B.W., Werner-Wasik M., et al. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 43 (1999) 293-298
30. Shaw E., Scott C., Souhami L., et al. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases. Int J Radiat Oncol Biol Phys 34 (1996) 647-654
31. Chamberlain M.C., Barba D., Kormanik P., and Shea W.M. Stereotactic radiosurgery for recurrent gliomas. Cancer 74 (1994) 1342-1347
32. Shrieve D.C., Alexander E., and Wen P.Y. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 36 (1995) 275-284
33. Veninga T., Langendijk H.A., Slotman B.J., et al. Reirradiation of primary brain tumours: survival, clinical response and prognostic factors. Radiother Oncol 59 (2001) 127-137
34. Combs S.E., Gutwein S., Thilmann C., et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma multiforme. J Neurooncol 74 (2005) 167-171
35. Vordermark D., Kolbl O., Ruprecht K., et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 5 (2005) 55
36. Grosu A.L., Weber W.A., Franz M., et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 511-519
37. Simon J.M., Cornu P., Boisserie G., et al. Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys 53 (2002) 67-74
38. Chan T.A., Weingart J.D., Parisi M., et al. Treatment of recurrent glioblastoma multiforme with gliasite brachytherapy. Int J Radiat Oncol Biol Phys 62 (2005) 1133-1139
39. Larson D.A., Prados M., Lamborn K.R., et al. Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys 54 (2002) 1397-1404
40. Mahajan A., McCutcheon I.E., Suki D., et al. Case-control study of stereotactic radiosurgery for recurrent glioblastoma multiforme. J Neurosurg 103 (2005) 210-217
41. 90Y-biotin radioimmunotherapy and temozolomide. Q J Nucl Med 48 (2004) 220-228
42. Reardon D.A., Akabani G., Coleman E., et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol 24 (2006) 115-122
43. Franceschi E., Cavallo G., Scopece L., et al. Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma. Br J Cancer 91 (2004) 1038-1044
44. Galanis E., Buckner J.C., Maurer M.J., et al. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial. Invest New Drugs 23 (2005) 495-503
45. Kappelle A.C., Postma T.J., Taphoorn M.J.B., et al. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56 (2001) 118-120
46. Boiardi A., Eoli E., Salmaggi A., et al. Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours. J Neurooncol 54 (2001) 39-47
47. Brandes A.A., Tosoni A., Amista P., et al. How effective is BCNU in recurrent glioblastoma in the modern era?. Neurology 63 (2004) 1281-1284
48. Fine H.A., Wen P.Y., Maher E.A., et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol 21 (2003) 2299-2304
49. Gwak HS, Youn SM, Kwon AH, et al. ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas: phase II study. J Neurooncol 2005, epub.
50. Brandes A.A., Basso U., Reni M., et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol 22 (2004) 1598-1604
51. Reardon DA, Quinn JA, Rich JN, et al. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 2005, epub.
52. Gruber M.L., and Buster W.P. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol 27 (2004) 33-38
53. Batchelor T.T., Gilbert M.R., Supko J.G., et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. J Neuro-oncol 6 (2004) 21-27
54. Hau P., Fabel K., Baumgart U., et al. Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma. Cancer 100 (2004) 1199-1207
55. Rich J.N., Reardon D.A., Peery T., et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22 (2004) 133-142
56. Haas-Kogan D.A., Prados M.D., Tihan T., et al. Epidermal growth factor receptor, protein kinase B/akt, and glioma response to erlotinib. J Natl Cancer Inst 97 (2005) 880-887
57. Mellinghoff I.K., Wang M.Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (2005) 2012-2024
58. Lassman A.B., Rossi M.R., Razier J.R., et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium trials 01-03 and 00-01. Clin Cancer Res 11 (2005) 7841-7850
59. Dresemann G. Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann Oncol 16 (2005) 1702-1708
60. Burch P.A., Bernath A.M., Cascino T.L., et al. A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas. Invest New Drugs 18 (2000) 275-280
61. Pipas J.M., Meyer L.P., Rhodes C.H., et al. A phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. J Neuro-Oncol 71 (2005) 301-305
62. Chang S.M., Kuhn J.G., Robbin H.I., et al. A phase II study of paclitaxel in patients with recurrent malignant glioma using different doses depending upon the concomitant use of anticonvulsants: a North American Brain Tumor Consortium report. Cancer 95 (2001) 417-422
63. Postma T.J., Heimans J.J., Luykx S.A., et al. A phase II study of paclitaxel in chemonaive patients with recurrent high-grade glioma. Ann Oncol 11 (2000) 409-413
64. Sanson M., Napolitano M., Yaya R., et al. Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J Neurooncol 50 (2000) 245-249
65. Reardon D.A., Quinn J.A., Vredenburgh J., et al. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer 103 (2005) 329-338
66. Kirby S., Gertzler S.Z., Mason W., et al. Phase 2 study of T138067-sodium in patients with malignant glioma: trial of the National Cancer Institute of Canada Clinical Trials Group. J Neuro-oncol 7 (2005) 183-188
67. Grossman S.A., Alavi J.B., Supko J.G., et al. Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas. J Neuro-oncol 7 (2005) 32-40
68. Puduvalli V.K., Yung W.K., Hess K.R., et al. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: a North American Brain Tumor Consortium study. J Clin Oncol 22 (2004) 4282-4289
69. Van den Bent M.J., Grisold W., Frappaz D., et al. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol 14 (2003) 1732-1734
70. Chamberlain M.C., and Tsao-Wei D.D. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer 100 (2004) 1213-1220
71. Rosenthal M.A., Ashley D.L., and Cher L. BCNU as second line therapy for recurrent high-grade glioma previously treated with temozolomide. J Clin Neurosci 11 (2004) 374-375
72. Brandes A.A., Tosoni A., Basso U., et al. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol 22 (2004) 4727-4734
73. Yajima N., Yamanaka R., Mine T., et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11 (2005) 5900-5911
74. Yamanaka R., Homma J., Yajima N., et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11 (2005) 4160-4167
75. Chang S.M., Kuhn J., Wen P., et al. Phase I/pharmakokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 22 (2004) 427-435
76. Chang S.M., Wen P., Cloughesy T., et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23 (2005) 357-361
77. Galanis E., Buckner J.C., Maurer M.J., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J Clin Oncol 23 (2005) 5294-5304
78. McDonald D.R., Cascino T.L., Schold S.C., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8 (1990) 1277-1280
79. Cloughesy T.F., Kuhn J., Robins H.I., et al. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium study. J Clin Oncol 23 (2005) 6647-6656
80. Keles G.E., Lamborn K.R., Chang S.M., et al. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 100 (2004) 41-46
81. Carson K., Grossman S.A., Fisher J.D., and Shaw E. Prognostic factors for survival in adult patients with recurrent glioma enrolled on New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium phase I and II clinical trials (Abstract). J Clin Oncol 23 Suppl. (2005) 116s
82. Bower M., Newlands E.S., Bleehen N.M., et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40 (1997) 484-488
83. Yung W.K.A., Prados M.D., Yaya-Tur R., et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 17 (1999) 2762-2771
84. Chang S.M., Theodosopoulos P., Lamborn K., et al. Temozolomide in the treatment of recurrent malignant glioma. Cancer 100 (2004) 605-611
85. Silvani A., Eoli M., Salmaggi A., et al. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive glioma patients. J Neurooncol 66 (2004) 203-208
86. Prados M.D., Yung W.K., Fine H.A., et al. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. J Neuro-oncol 6 (2004) 33-37
87. Spence A.M., Peterson R.A., Scharnhorst J.D., Silbergeld D.L., and Rostomily R.C. Phase II study of concurrent continuous temozolomide and tamoxifen for recurrent malignant astrocytic gliomas. J Neurooncol 70 (2004) 91-95
88. Groves M.D., Puduvalli V.K., Hess K.R., et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20 (2002) 1383-1388
89. Chua S.L., Rosenthal M.A., Wong S.S., et al. Phase 2 study of temozolomide and caelyx in patients with recurrent glioblastoma multiforme. J Neuro-oncol 6 (2004) 38-43
90. Poisson M., Pereon Y., Chiras J., and Delattre J.Y. Treatment of recurrent malignant supratentorial gliomas with carboplatin. J Neurooncol 10 (1991) 139-144
91. Gregor A., Lind M., Newman H., et al. Phase II studies of RMP-7 and carboplatin in the treatment of recurrent high-grade glioma. J Neurooncol 44 (1999) 137-145
92. Stein M.E., Kuten A., Drumea K., Goldsher D., and Tzuk-Shina Z. Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure. J Surg Oncol 71 (1999) 167-170
93. Ameri A., Poisson M., Chauveinc L., Chen Q.M., and Delattre J.Y. Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: a phase II study. J Neurooncol 32 (1997) 155-160
94. Sanson M., Ameri A., Monjour A., et al. Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. Eur J Cancer 32A (1996) 2229-2235